The case for informative phase 2 trials in osteosarcoma.

[1]  D. Hawkins,et al.  Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Blay,et al.  Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. , 2016, The Lancet. Oncology.

[3]  R. Goldsby,et al.  Rapid Protocol Enrollment in Osteosarcoma: A Report From the Children's Oncology Group , 2016, Pediatric blood & cancer.

[4]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  R. Goldsby,et al.  Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group. , 2013, European journal of cancer.

[7]  J. Healey,et al.  Addition of pamidronate to chemotherapy for the treatment of osteosarcoma , 2011, Cancer.

[8]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[9]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.